TINs Webinar: Antisense oligonucleotides as potential treatments for inherited retinal dystrophies

Antisense oligonucleotides (AONs) can be used to alter many aspects of gene expression, from splice isoform switching to reducing, or increasing, gene expression. The retina is an accessible part of the nervous system and is an ideal paradigm to study how AONs can be used to combat neurodegeneration. During this webinar, Prof. Mike Cheetham from the Institute of Ophthalmology will give an overview of AON design and show how they can be used as therapies for inherited retinal dystrophies (IRDs), from stem cell derived models of disease, to in vivo and clinical trials. This will exemplify the potential of AONs to treat genetic disease, and IRDs in particular. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biome